LKFT Lakefront Biotherapeutics - American Depositary Shares
Acerca de Lakefront Biotherapeutics - American Depositary Shares Descripción general de la empresa de Wikipedia
Lakefront Biotherapeutics is a Belgian pharmaceutical research company which was founded in 1999. Its headquarters are located in Mechelen and has additional locations in Leiden, Romainville, Basel, Milan, Madrid, Boston and Zagreb.
Leer más
Lakefront Biotherapeutics (formerly known as Galapagos NV and Galapagos Genomics) is a Belgian pharmaceutical research company which was founded in 1999. Its headquarters are located in Mechelen and has additional locations in Leiden, Romainville, Basel, Milan, Madrid, Boston and Zagreb.
The company develops drugs against rheumatoid arthritis, Crohn's disease, ulcerative colitis, psoriasis, systemic lupus erythematosus and cystic fibrosis.
History
Galapagos Genomics NV was founded in 1999 as a joint venture between Crucell and Tibotec. The company later changed its name to Galapagos NV and completed its initial public offering on Euronext Amsterdam and Euronext Brussels in May 2005.
The company uses a technological platform for its research, which is based on adenoviruses to introduce human gene sequences into a wide variety of human cell lines to knock-in or knock-down specific proteins.
In 2019, Gilead Sciences and Galapagos entered into transformative research and development collaboration. Gilead and Galapagos have also agreed to amend certain terms around the development and commercialization of filgotinib.
In June 2022, the business announced it would acquire CellPoint for €125 million, with milestones of up to €100 million and AboundBio for $14million.
Effective April 1, 2022 Paul Stoffels replaced cofounder and CEO of 20 years Onno van de Stolpe.
In April 2026 the company was renamed to Lakefront Biotherapeutics.
Company
A German company, Galapagos Biopharma Germany GmbH, was established in 2019 and is headquartered in Munich, Germany. In December 2021, the company established an Austrian subsidiary, Galapagos Biopharma Austria GmbH, headquartered in Vienna, Austria.
Drugs
Filgotinib (GLPG0634) a selective inhibitor of JAK1 (Janus kinase 1) being developed for the treatment of rheumatoid arthritis and potentially Crohn's disease.
GLPG1205: a first-in-class GPR84-inhibitor currently under research for the treatment of inflammatory bowel disease.
Fuente: Wikipedia (Inglés), CC BY-SA 4.0 · Ver en Wikipedia ↗
Aún no hay datos fundamentales para este ticker.
Activistas y propietarios del %+ 5 3 tenencias
Inversores que presentaron el Anexo 13D de la SEC — propiedad beneficiosa superior al % 5 con la intención de influir en el emisor (participaciones activistas, campañas de la junta directiva, M&A). Cada fila muestra el estado conocido más reciente de la posición de ese declarante.
| Declarante | Presentado | Participación | Estado | Propósito | Presentación |
|---|---|---|---|---|---|
| EcoR1 Capital, LLC, Oleg Nodelman, EcoR1 Capital Fund Qualified, L.P., EcoR1 Capital Fund, L.P. ×4 presentaciones | 28 de julio de 2025 | 13,22% | Enmienda | — | SEC |
| TANG CAPITAL MANAGEMENT, LLC, KEVIN TANG, TANG CAPITAL PARTNERS, LP, TANG CAPITAL PARTNERS INTERNATIONAL, LP, TANG CAPITAL PARTNERS III, INC, TANG CAPITAL PARTNERS IV, INC, CONCENTRA BIOSCIENCES, LLC | 14 de febrero de 2025 | 7,50% | Presentación inicial | — | SEC |
| Van Herk Investments B.V., Van Herk Investments THI B.V., Van Herk Private Equity Investments B.V., Stichting Administratiekantoor Penulata, Van Herk Management Services B.V., Onroerend Goed Beheer – en Beleggingsmaatschappij A. van Herk B.V., A. van Herk Holding B.V., Stichting Administratiekantoor Abchrys, Adrianus van Herk | 2 de noviembre de 2021 | — | Presentación inicial | Campaña de la junta directiva | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Propiedad de ETFs Mantenido por 18 ETFs
El peso refleja solo las tenencias directas de acciones (N-PORT); los fondos apalancados o basados en derivados pueden tener exposición adicional a swaps no mostrada.
| Fondo | Ponderación | Unidades | A fecha de | Fuente |
|---|---|---|---|---|
| EWK · iShares, Inc. | 0,58% | 37 133 SH | 8 de agosto de 2026 | Diario |
| QQQS · Invesco Exchange-Traded Fund Trust … | 0,47% | 3 949 SH | 8 de agosto de 2026 | Diario |
| IBB · iShares Trust | 0,08% | 305 498 SH | 8 de agosto de 2026 | Diario |
| PDN · Invesco Exchange-Traded Fund Trust … | 0,07% | 9 655 SH | 8 de agosto de 2026 | Diario |
| IEUS · iShares Trust | 0,05% | 3 396 SH | 8 de agosto de 2026 | Diario |
| VSS · VANGUARD INTERNATIONAL EQUITY INDEX… | 0,04% | 188 173 SH | 8 de agosto de 2026 | Diario |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0,03% | 815 SH | 8 de agosto de 2026 | Diario |
| SCZ · iShares Trust | 0,02% | 113 209 SH | 8 de agosto de 2026 | Diario |
| VGK · VANGUARD INTERNATIONAL EQUITY INDEX… | 0,01% | 119 870 SH | 8 de agosto de 2026 | Diario |
| WSML · iShares Trust | 0,01% | 2 543 SH | 8 de agosto de 2026 | Diario |
| IEUR · iShares Trust | 0,01% | 27 247 SH | 8 de agosto de 2026 | Diario |
| IEFA · iShares Trust | 0,00% | 320 356 SH | 8 de agosto de 2026 | Diario |
| IDEV · iShares Trust | 0,00% | 40 908 SH | 8 de agosto de 2026 | Diario |
| IXUS · iShares Trust | 0,00% | 62 087 SH | 8 de agosto de 2026 | Diario |
| VXUS · VANGUARD STAR FUNDS | 0,00% | 717 158 SH | 8 de agosto de 2026 | Diario |
| VT · VANGUARD INTERNATIONAL EQUITY INDEX… | 0,00% | 36 160 SH | 8 de agosto de 2026 | Diario |
| VEA · VANGUARD TAX-MANAGED FUNDS | 0,00% | 483 750 SH | 8 de agosto de 2026 | Diario |
| VSGX · VANGUARD WORLD FUND | 0,00% | 9 595 SH | 8 de agosto de 2026 | Diario |